COPN Cosmo N.V.
Partial data58.20CHF+2.28%Mkt Cap: 1.15B $P/E: —49d ago
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-ass…
Industry Peers
Drug Manufacturers - General$1.03TUSDP/E 38.9
LLY
Eli Lilly and Company$983.06BUSDP/E 38.6
$613.99BUSDP/E 29.5
$471.27BUSDP/E 75.3
ABBV
AbbVie Inc.$450.29BUSDP/E 75.6
$350.19BUSDP/E 112.7
$326.64BUSDP/E 23.4
MRK
Merck & Co., Inc.$350.30BUSDP/E 112.5
ROG
Roche Holding AG$322.35BUSDP/E 20.8
$254.20BUSDP/E 22.3
$267.60BUSDP/E 21.3
$260.71BUSDP/E 25.2
NVS
Novartis AG$258.40BUSDP/E 21.8
$245.99BUSDP/E 23.7
$234.91BUSDP/E 25.3
$217.66BUSDP/E 25.0
$201.58BUSDP/E 24.0
AMGN
Amgen Inc.$212.52BUSDP/E 25.0
$178.84BUSD
GILD
Gilead Sciences, Inc.$174.28BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Cosmo (SWX:COPN) Reports Weaker Half Year Results, Is It Still A Bargain? Cosmo (SWX:COPN) is back in focus after reporting half year 2026 results, with lower sales of €50.24 million and a higher net loss of €4.75 million compared with the prior year period. See our latest analysis for Cosmo. Despite the weaker half year result, Cosmo’s recent 1 day share price return of 7.82% and 7 day share price return of 9.37% suggest short term momentum is improving. However, the year to date share price return is still down 34.63% and the 5 year total shareholder return is... | ||